MENU

Colorectal and SI Cancer Translational Research Disease Group

Understanding the genetic alterations that lead to colorectal cancer is essential to fighting the disease. At Fox Chase, a multidisciplinary team of researchers and clinicians meets regularly to review translational research initiatives to identify and characterize new biomarkers of colorectal and SI cancers that lead to new, innovative prevention and targeted therapy options for our patients.

Faculty Group Members

Wafik S. El-Deiry, MD, PhD, FACPWafik El-Deiry, MD, PhD, FACP

Sanjeevani Arora, PhDSanjeevani Arora, PhD

Doctor Astsatutov photoIgor Astsaturov, MD, PhD
4.7
52 Patient Satisfaction Ratings

Mark Andrake, PhDMark Andrake, PhD

Alfonso Bellacosa, MD, PhDAlfonso Bellacosa, MD, PhD

Wen-Chi Chang, MD Wen-Chi Chang, PhD

Jonathan Cheng, MDJonathan Cheng, MD

Jon Chernoff, MD, PhDJonathan Chernoff, MD, PhD

Margie L. Clapper, PhDMargie Clapper, PhD

Denise Connelly, PhDDenise Connolly, PhD

Harry Cooper, MDHarry Cooper, MD

Crystal Denlinger, MD, FACP
4.9
77 Patient Satisfaction Ratings

John Michael Daly, MDJohn Daly, MD, FACS, FRCSI (Hon), FRCSG (Hon)
4.8
50 Patient Satisfaction Ratings

Efrat Dotan, MDEfrat Dotan, MD
4.9
75 Patient Satisfaction Ratings

James S. Duncan, PhDJames Duncan, PhD

Paul Engstrom, MDPaul Engstrom, MD, FACP
4.8
45 Patient Satisfaction Ratings

Jeffrey M. Farma, MD, FACSJeffrey Farma, MD, FACS
4.8
150 Patient Satisfaction Ratings

Erica Golemis, PhD

Sergei Grivennikov, PhDSergei Grivennikov, PhD

Dr. Michael HallMichael Hall, MD, MS
4.9
57 Patient Satisfaction Ratings

Jean-Pierre Issa, MD

Joshua Meyer, MDJoshua Meyer, MD
4.9
47 Patient Satisfaction Ratings

Juhi Mittal, MDJuhi Mittal, MD

Minhuyen Nguyen, MD, AGAFMinhhuyen Nguyen, MD, AGAF, FACP
4.9
97 Patient Satisfaction Ratings

Anthony Olszanski, MDAnthony Olszanski, MD, RPh
4.9
60 Patient Satisfaction Ratings

Eric A. Ross, PhD, ScMEric Ross, PhD, ScM

Carmen Sapienza, PhD

E.R. Sigurdson, MD, PhD, FACSElin Sigurdson, MD, PhD, FACS, FRCS (C)
4.8
102 Patient Satisfaction Ratings

Namrata (Neena) Vijayvergia, MDNamrata (Neena) Vijayvergia, MD
4.9
49 Patient Satisfaction Ratings

David Weinberg, MD, MScDavid Weinberg, MD, MSc
4.9
56 Patient Satisfaction Ratings

David Wiest, PhDDavid Wiest, PhD

J.Q. Yu, MD, FRCPCJian Q. (Michael) Yu, MD, FACNM, FRCPC
Research Faculty
Fellows
Additional Members
  • Suzanne Beers, Director of Development, Institutional Advancement

Clinical and research fellows are welcome to attend this TRDG meeting. Also, any faculty who have an interest in participation please communicate with Wafik El-Deiry or Alison Conn.

Funding Opportunities

Support for our research initiatives allows Fox Chase to have a continued stake in the future of translational research, and the Center encourages our researchers and clinician to apply for grant funding to advance the mission to prevail over cancer. Below is a list of current research funding opportunities:

NCI Clinical and Translation Exploratory/Development Studies (R21)

NCI SPORE Program opportunities

NCI U01 Program opportunities

NCI P01 Program opportunities

Giving

As a nonprofit institution, support from donors allows Fox Chase to remain one of the top cancer research and treatment centers in the country. Through donations, planned gifts, and membership to our giving societies, our supporters ensure Fox Chase remains at the forefront of colorectal cancer research and novel treatment options that save lives.

To give to the colorectal and SI cancer research program, visit foxchase.org/giving.

Related News

Sergei Grivennikov, PhD

Fox Chase Cancer Center and the Lewis Katz School of Medicine Announce American Cancer Society Institutional Research Grant Winners

PHILADELPHIA (December 22, 2017) – Fox Chase Cancer Center and the Lewis Katz School of Medicine are pleased to announce the winners of its American Cancer Society Institutional Research Grant (IRG) Pilot Project Competition for Junior Investigators: Sergei Grivennikov, PhD, and Elias Obeid, MD, MPH, assistant professors at Fox Chase, and Rongsheng (Ross) Wang, PhD, assistant professor at the Lewis Katz School of Medicine at Temple University.

Keep Reading
Blood-Based Test

Blood-Based Test Could Identify Risk for Inherited Colorectal Cancer

PHILADELPHIA (September 10, 2015) – The genetic mutations responsible for most inherited colorectal cancers are unknown, hindering diagnosis and treatment options for about 20% of all patients with colorectal cancer in the United States. Fox Chase Cancer Center researchers now show that mutations in specific genes involved in DNA repair occur more frequently in the blood cells of patients with familial colorectal cancer than in the general population. The findings, reported September 10th in Gastroenterology, pave the way for the development of a simple, inexpensive blood-based diagnostic test and could potentially improve personalized therapeutic strategies.

Keep Reading
Researchers Developing New Targeted and Immune Therapies for Colorectal Cancer Molecular Subtypes

Researchers Developing New Targeted and Immune Therapies for Colorectal Cancer Molecular Subtypes

CHICAGO (May 27, 2015) — Researchers from Fox Chase Cancer Center in Philadelphia recently collaborated with Caris Life Sciences® to conduct three separate studies related to precision medicine, particularly in colorectal cancers. These findings will be highlighted at the upcoming 2015 American Society of Clinical Oncology Annual Meeting.

Keep Reading
New Targeted Treatment IMMU-130 Shows Promise in Patients with Metastatic Colon Cancer

New Targeted Treatment IMMU-130 Shows Promise in Patients with Metastatic Colon Cancer

CHICAGO (May 18, 2015) — Although various drugs have improved outcomes for metastatic colon cancer patients, researchers continually strive to find new agents to improve treatment. Antibody-drug conjugates are a promising option, due to the fact that they can deliver chemotherapy directly into...

Keep Reading

Connect with Fox Chase